Beyond Tax Benefits: Portfolio Opportunities In A Pfizer-Allergan Deal
This article was originally published in Scrip
Executive Summary
Pfizer Inc. and Allergan plc continue to be in closed-door discussions regarding a potential merger that could significantly cut Pfizer's tax rate due to Allergan's Irish corporate base, but Allergan also has several commercial products and research-stage assets that could fill gaps in Pfizer's portfolio.
You may also be interested in...
Allergan’s Namesake Acquisition Looks Well-Timed As Established Brands Falter
Allergan’s net product revenue in the third quarter fell slightly below analyst consensus, but revenue from the company’s 2015 purchase of Botox, Restasis and other products softened declines for established products Namenda and Asacol.
Finance Watch: Karuna, Cerevel And Others Benefit From Improving Biotech Sentiment
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.
Anthos Takes On Pharma Giants In Factor XI Anticoagulation Space
CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.